Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021
48 slides from Fresenius SE & Co. KGaA's conference presentation, Jan 18, 2021
Slide 1: UniCredit Kepler Cheuvreux 20th German Corporate Conference – Virtual
UniCredit Kepler Cheuvreux 20th German Corporate Conference – Virtual 18-19 January 2021 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: A Global Leader in Health Care Products and Services
A Global Leader in Health Care Products and Services ~€35.4 bn in Sales Long-term opportunities (FY/2019) in growing, non-cyclical Leading market positions markets Global presence in 309,000+ employees Strong financial performance 100+ countries worldwide and cash flow generation (as of September 30
Slide 4: Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets
Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets 2019 Sales by Region Sales in € bn 6% Africa 1 Latin America 4% 1% 1 CAGR 35,524 35,409 Asia-Pacific 33,886 33,530 11% €35.4 bn 29,471 27,995 Europe 43% North America 41% 4,688 4,599 4,830 4,599 1 4,561 4,001 4,302 2015 2016 2017 20
Slide 5: Strong Track Record of Organic Sales Growth in All Business Segments
Fresenius Group: Strong Track Record of Organic Sales Growth in All Business Segments Fresenius Group Business Segments 5% CAGR 8% 7% 7% 7% 7% 6% 6% 6% 6% 5% 5% 5% 4% 4% 4% ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18 ´19 16% 16% 6% 6% 5% 5% 4% 4% 3% 3% ´15 ´16 ´17 ´18 ´19 ´15 ´16 ´17 ´18
Slide 6: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: ~32% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc
Slide 7: Fresenius Medical Care: Global Dialysis Market Leader
Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating ~349,000 patients1 in ~4,000 clinics1 Global Dialysis Market 2019: • Provide highest standard of product quality and • ~€80 bn • ~6% patient growth p.a. pat
Slide 8: Fresenius Kabi: A Leading Global Hospital Supplier
Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2019: • Leading market positions • ~€97 bn Growth Drivers: • Patent expirations, rising demand
Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator
Fresenius Helios: Europe’s Largest Private Hospital Operator • Market leader in size and quality with excellent Market Dynamics growth prospects Hospital Market Size: • ~5%1 share in German acute care hospital • ~€102 bn2 German Acute Care Hospital Market ~12%1 share in Spanish private hospital mark
Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist
Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin
Slide 11: Global Trends offer Growth Opportunities for Fresenius
Global Trends offer Growth Opportunities for Fresenius Aging Population Growing healthcare sector 6.3 % by 2050 Growth in emerging In 2019: 9% of the world 16 % markets + population is > age 651 over the next decade2 p.a. Increasing national income Chronically ill patients GDP per capita quadrupled
Slide 12: Fresenius Group: Growth Areas
Fresenius Group: Growth Areas Worldwide growing Growing Markets Marketing dialysis market with High Entry Attractive markets of existing Barriers value chain Standardizing Attractive Product Market Strengthening medical procedures Pipeline consolidation and extension of value chain Home dialysis Ent
Slide 13: Medium-term Growth Targets 2020 – 2023 (CAGRs)
Fresenius Group: Medium-term Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid-size acquisitions) confirmed Organic net income1 growth 5 – 9% (plus ~1% small to mid-size acquisitions) confirmed 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA B
Slide 14: The Fresenius Strategy
The Fresenius Strategy Improve profitability Drive Quality Internation- alization Hospital Dialysis supplies & products & Innovation services services Employees Better Hospital projects & medicine and Hospital operations services health care services for ever more people Forward thinking healthcare
Slide 15: Our ESG Priorities: Patients, Employees and Compliance
Our ESG Priorities: Patients, Employees and Compliance Serving the well-being Doing the right thing Being an attractive Protecting nature as Caring for of the patient employer the basis of life human rights Quality of medical Code of Conduct Personnel structure Water No exploitative nor ou
Slide 16: ESG Rating Overview: Continuous Improvement through Reporting and Engagement
ESG Rating Overview: Continuous Improvement through Reporting and Engagement Current Score CDP Climate: B 50/100 Prime C BBB 19.6 Low Risk CDP Water: C DJSI Europe CDP Climate: C 28.5 Medium Sector Average C- BBB - A 28 / 100 CDP Water: Risk New Previous Score CDP Climate: C Prime C BB 39/100 method
Slide 17: Sustainability/ESG: Decisive Steps for 2020
Sustainability/ESG: Decisive Steps for 2020 Our Priorities • “Better medicine for more people” • Patients: Quality of products and services • People: Being an attractive employer • Compliance: Doing the right thing Sustainability Governance Remuneration • CEO sponsors Group sustainability efforts •
Slide 18: Capital Deployment Focuses on Sustainable Value Creation
Fresenius Group: Capital Deployment Focuses on Sustainable Value Creation Investments in own business Strategic acquisitions Dividends Share buy backs Leverage ratio 3.0-3.5 UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability
Slide 19: Proven Track Record of Deleveraging
Fresenius Group: Proven Track Record of Deleveraging Net Debt/EBITDA1 Hospitals from 4 3.7x 3 3.6x 3.6x 3 3.5x 3.5x 3 3,5 3.5 3.2x 3.4x 3 3.0x 3.0x 3.0x 3.1x 3 2.7x 2.8x 2.7x 2.7x 2.6x 2.7x 2,5 2.5 2.2x 2.6x 2.6x 2.5x 2.3x 2.3x 2 2 2002 2003 2004 2005 Q1/06 2006 2007 2008 2009 2010 2011 2012 2013 20
Slide 20: Fresenius SE: Earnings-Linked Dividend Policy
Fresenius SE: Earnings-Linked Dividend Policy 2019 Pay-out Ratio: 24% Dividend Policy 0.84 0.80 • Dividend growth aligned to EPS 1 0.75 growth • Pay-out Ratio: 20% to 25% 0.62 0.55 Pay-out Ratio 0.44 0.42 € per share 0.37 0.32 Track record 0.29 Dividend 0.25 distribution 0.23 (€m) 25% 24% 24% 24% •
Slide 21: Review Q3/20
Review Q3/20 UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 21
Slide 22: Fresenius Group Q3/20 – Key Messages
Fresenius Group Q3/20 – Key Messages • Resilient business model delivers healthy 5% cc sales growth, good cash flow development • Group-wide cost optimization fostered during the pandemic – benefits to stay in post-COVID world • Positive net income growth – Fresenius Group has passed the trough • Fr
Slide 23: Fresenius Kabi: Headwinds in the US, Europe recovery, China returns to growth
Fresenius Kabi: Whilst headwinds weigh on the US, Europe sees a recovery and China returns to growth North America • Fewer elective treatments and temporary manufacturing issues outweighed extra demand for COVID-19 related products • Underutilization of capacities impacts profitability • Incremental
Slide 24: Fresenius Kabi: Biosimilars progress; Medical Devices plowing ahead
Fresenius Kabi: Progress of biosimilars business in line with expectations; Medical Devices plowing ahead Biosimilars • Fresenius gains traction in European adalimumab market – recent tender wins • Competitive product offering - ongoing further optimization of cost base • Cooperation with pharmaceut
Slide 25: Helios Germany: Resilient development with sales growth in Q3
Helios Germany: Resilient development with sales growth in Q3 due to recovery of elective procedures Helios Germany Recovery of elective procedures • Clear trend of increasing sequential case numbers - holiday-related dip in August • Cumulative YoY gap in case numbers still significant • State-of-th
Slide 26: Helios Spain: Recovery of elective treatments
Helios Spain: Recovery of elective treatments Admissions 2020 vs. 2019 100% 80% 60% 40% 20% 0% -20% -40% -60% -80% -100% Jan Feb Mar Apr May Jun Jul Aug Sep Oct Outpatient Surgeries (ambulatory) Diagnostics - MRIs UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius SE & Co.
Slide 27: Helios Spain: Significant growth in Q3 based on catch-up effects
Helios Spain: Significant growth in Q3 based on catch-up effects Helios Spain Recovery of elective procedures Regulatory framework • Pent-up demand led to YoY growth • Reimbursement negotiations with virtually • Usual holiday pattern with significantly all private Health Insurance Companies fewer ca
Slide 28: Fresenius Vamed: Ongoing significant COVID-19 headwinds
Fresenius Vamed: Ongoing significant COVID-19 headwinds in project and service business Project Business Service Business • Project order intake continued to be • Lower capacities due to health authority marked by delays and cancellations induced capacity restrictions • Global execution delays due t
Slide 29: Fresenius in excellent shape to unleash accelerated growth after COVID-19
Fresenius Group Q3/20: Fresenius in excellent shape to unleash accelerated growth following the COVID-19 pandemic Trends accelerated by COVID-19 • Core competence of Fresenius High quality healthcare • Long-standing track record products and services • Market-leading positions • We produce where we
Slide 30: Financial Review Q3/20
Financial Review Q3/20 UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 30
Slide 31: Fresenius Group: Q3/20 Profit and Loss Statement
Fresenius Group: Q3/20 Profit and Loss Statement Sales EBIT +5% 1% Net Income Q3/20: €8,918 m Q3/20: €1,113 m 1% Income Tax Rate Net Interest Q3/20: €427 m 22.0% -€154 m Q3/19: 23.1% Q3/19: -€171 m All growth rates in constant currency (cc) Before special items Net income attributable to shareholder
Slide 32: Fresenius Group: Q3/20 Business Segment Growth
Fresenius Group: Q3/20 Business Segment Growth Organic sales growth EBIT growth (cc) +3% +7% +2% -4% +6% +20% -10% -133% +3% +1% All figures before special items For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-ce
Slide 33: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow Operating CF Capex (net) Free Cash Flow1 €m Q3/2020 LTM Margin Q3/2020 LTM Margin Q3/2020 LTM Margin 746 24.5% -240 -5.9% 506 18.6% 225 16.3% -157 -10.5% 68 5.8% 275 9.9% -97 -5.0% 178 4.9% -4 0.2% -18 -4.2% -22 -4.0% Corporate/Other -43 n.a. -5 n.a. -48 n.a. 566 11.7% -27
Slide 34: FY/20 Financial Outlook by Business Segment
Fresenius Group: FY/20 Financial Outlook by Business Segment (including COVID-19 effects) FY/19 Q1-3/20 FY/20e2 €m (except otherwise stated) Base1 Actual FY/20e2 New Sales growth (org) 6,919 5,161 +2% to +5% confirmed EBIT growth (cc) 1,205 859 -6% to -3% confirmed Sales growth (org) 9,234 7,181 +1%
Slide 35: FY/20 Financial Guidance
Fresenius Group: FY/20 Financial Guidance (including COVID-19 effects) €m FY/19 Q1-3/20 FY/20e2,3 (except otherwise stated) Base1 Actual2 FY/20e2,3 New Sales growth (cc) 35,409 +5% +3% to +6% confirmed Net income4 1,879 -4% -4% to +1% confirmed growth (cc) 1 Before special items, including IFRS 16 e
Slide 36: Attachments
Attachments UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 36
Slide 37: Fresenius Kabi: Q3 & Q1-3/20 Organic Sales Growth by Regions
Fresenius Kabi: Q3 & Q1-3/20 Organic Sales Growth by Regions Δ YoY Δ YoY €m Q3/20 organic Q1-3/20 organic North America 558 -5% 1,827 1% Europe 581 5% 1,778 5% Emerging Markets 555 6% 1,556 3% Total sales 1,694 2% 5,161 3% UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 © Fresenius
Slide 38: Fresenius Kabi: Organic Sales Growth by Product Segment
Fresenius Kabi: Q3 & Q1-3/20 Organic Sales Growth by Product Segment €m Q3/20 Δ YoY Q1-3/20 Δ YoY organic organic IV Drugs 687 -2% 2,224 3% Infusion Therapy 191 -3% 568 -5% Clinical Nutrition 500 7% 1,417 4% Medical Devices/ 316 5% 952 7% Transfusion Technology Total sales 1,694 2% 5,161 3% UniCredi
Slide 39: Fresenius Kabi: Q3 & Q1-3/20 EBIT Growth
Fresenius Kabi: Q3 & Q1-3/20 EBIT Growth €m Q3/20 Δ YoY cc Q1-3/20 Δ YoY cc North America 167 -20% 660 -6% Margin 29.9% -640 bps 36.1% -260 bps Europe 86 15% 270 13% Margin 14.8% +150 bps 15.2% +110 bps Emerging Markets 140 12% 318 -4% Margin 25.2% +180 bps 20.4% -120 bps Corporate and Corporate R&D
Slide 40: Fresenius Helios: Q3 & Q1-3/20 Key Financials
Fresenius Helios: Q3 & Q1-3/20 Key Financials €m Q3/20 Δ YoY cc Q1-3/20 Δ YoY cc Total sales 2,400 6%1 7,181 3%1 Thereof Helios Germany 1,529 4%1 4,703 5%1 Thereof Helios Spain 870 10%1 2,476 -2%1 Total EBIT 225 20% 697 -5% Margin 9.4% 100 bps 9.7% -90 bps Thereof Helios Germany 133 2% 445 3% Margin
Slide 41: Fresenius Helios: Key Metrics
Fresenius Helios: Key Metrics Q1-3/20 FY/19 Δ No. of hospitals Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Spain 53 51 4% (Hospitals) No. of beds Germany 28,852 28,907 0% - Acute care hospitals 28,325 28,380 0% No. of beds Spain 7,912 7,288 9% (Hospitals) Admissions Germany (ac
Slide 42: Fresenius Vamed: Q3 & Q1-3/20 Key Financials
Fresenius Vamed: Q3 & Q1-3/20 Key Financials €m Q3/20 Δ YoY cc Q1-3/20 Δ YoY cc Total sales 517 -8% 1,491 1% Thereof organic sales -10% -1% Project business 140 -34% 428 -4% Service business 377 8% 1,063 4% Total EBIT -11 -133% -10 -115% Order intake1 188 -22% 362 -51% Order backlog1 2,786 -3%2 1 Pr
Slide 43: Fresenius Group: Q3/20 Key Financials
Fresenius Group: Q3/20 Key Financials €m Q3/201 special Q3/20 Δ YoY cc1 items reported Sales 8,918 - 8,918 5% EBIT 1,113 - 1,113 1% Net interest -154 - -154 6% Income taxes -211 - -211 4% Net income2 427 - 427 1% 1 Before special items 2 Net income attributable to shareholders of Fresenius SE & Co.
Slide 44: Calculation of Noncontrolling Interests
Fresenius Group: Calculation of Noncontrolling Interests €m Q1-3/20 Q1-3/19 Earnings before tax and noncontrolling interests 2,866 2,869 Taxes -651 -662 Noncontrolling interests, thereof -913 -834 Fresenius Medical Care net income not attributable to Fresenius -670 -599 (Q3/20: ~68%) Noncontrolling
Slide 45: Fresenius Group: Cash Flow
Fresenius Group: Cash Flow €m Q3/20 LTM Margin Δ YoY Operating Cash Flow 1,199 17.8% -19% Capex (net) -517 -6.7% 10% Free Cash Flow 682 11.1% -25% (before acquisitions and dividends) Acquisitions (net) -77 Dividends -790 Free Cash Flow -185 6.2% -125% (after acquisitions and dividends) UniCredit Kep
Slide 46: Estimated COVID-19 effects Q3/Q1-3 2020
Estimated COVID-19 effects Q3/Q1-3 2020 Growth cc Estimated as reported COVID-19 impact cc incl. COVID-19 Q3/201 Q1-3/201 Q3/201 Q1-3/201 Sales +5% +5% -1% to -2% -2% to -3% Net income2 +1% -4% -0% to -4% -6% to -10% 1 Before special items 2 Net income attributable to shareholders of Fresenius SE &
Slide 47: Major Long Term Debt Maturities Well-balanced Maturity Profile
1 Fresenius Group: Major Long Term Debt Maturities Well-balanced Maturity Profile Except for the €750m Term Loan all major €m maturities have been refinanced already 4.000 4,000 Maturity 4.5 years on 3.000 3,000 average 2.005 2,000 2.000 1.899 2.071 738 584 1.000 1,000 684 1.674 500 1.657 986 1.100
Slide 48: Financial Calendar / Contact
Financial Calendar / Contact Financial Calendar 23 February 2021 Results FY/20 06 May 2021 Results Q1/21 21 May 2021 Annual General Meeting 30 July 2021 Results Q2/21 02 November 2021 Results Q3/21 Please note that these dates could be subject to change. Contact Investor Relations & Sustainability F
Fresenius SE & Co. KGaA — UniCredit Kepler Cheuvreux 20th German Corporate Conference 2021 on 6ix